#USA #New York #biotech #Immunic #Conferences

Immunic Inc. Set to Showcase Innovations at Multiple Upcoming Conferences

Immunic, Inc. (Nasdaq: IMUX), a pioneering biotechnology firm focused on developing orally administered therapies for chronic inflammatory and autoimmune diseases, has announced its participation in several prestigious investor and scientific conferences scheduled for June 2025. These events present a significant opportunity for the company to share its innovative research and engage with key stakeholders in the healthcare industry.

Highlights of Upcoming Conferences

• - Jefferies Healthcare Conference (June 3-5)

The conference will be held in New York, where Immunic’s CEO Dr. Daniel Vitt will provide a comprehensive overview of the company’s strategies and projects. His presentation is scheduled for June 5th at 4:55 PM ET, with a live webcast available on Immunic's website. Furthermore, members of the management team, including Jason Tardio, CFO Glenn Whaley, and Jessica Breu, will conduct one-on-one meetings with potential investors to discuss the company’s pipeline and investment opportunities.

• - 4th RSC Anglo-Nordic Medicinal Chemistry Symposium (June 10-13)

Taking place in Snekkersten, Denmark, Dr. Christian Gege, the Head of Intellectual Property, will present groundbreaking preclinical data featuring antiviral candidates derived from the lead asset, vidofludimus calcium (IMU-838). His presentation will include a flash talk and a poster on the accelerated development of new antiviral therapies crucial for pandemic preparedness.

• - UBS Life Sciences Conference (June 11)

This event will be hosted in London, where Dr. Vitt and Ms. Breu will represent Immunic. Interested parties can get in touch with Jessica Breu to arrange meetings, facilitating deeper discussions about the company's advancements and future projects.

• - BIO International Convention 2025 (June 16-19)

The convention in Boston will see participation from Immunic's management and business development teams, focusing on collaborative partnerships to drive innovation in biotechnology. Interested stakeholders are encouraged to schedule meetings via the BIO International Convention partnering portal or directly with the team.

• - 11th Congress of the European Academy of Neurology (EAN) – Helsinki 2025 (June 21-24)

Members of Immunic's research team will attend this congress where they will share valuable insights on the nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838). The presentation will include data on its neuroprotective effects concerning multiple sclerosis, further highlighted through an ePresentation session.

• - Accelerating Bio-Innovation (ABI) Conference 2025 (June 23-25)

This conference in Cambridge, MA, organized in collaboration with Royalty Pharma, will feature Dr. Vitt and Mr. Tardio discussing the future directions of biotechnology and how Immunic is positioning itself as a leader in the sector.

About Immunic's Developmental Pipeline

Immunic, Inc. is making strides with its lead candidate, vidofludimus calcium (IMU-838), currently in phase 3 clinical trials targeting relapsing multiple sclerosis, with data expected by the end of 2026. The promising results from earlier trials have established the drug's therapeutic potential, demonstrating its unique dual action as a neuroprotective and anti-inflammatory agent.

The company is also progressing with additional candidates like IMU-856, aimed at restoring intestinal barrier function, which could benefit patients with various gastrointestinal diseases. IMU-381 is in preclinical testing and is designed to tackle gastrointestinal ailments more aggressively.

For more information regarding Immunic's advancements and upcoming presentations, stakeholders can visit their official website for real-time updates and conference details.

Conclusion

As Immunic prepares for these conferences, it is set to strengthen its position in the biotechnology industry, showcasing its commitment to innovation and patient-centered solutions. The data presented will not only highlight the efficacy of their current therapies but also pave the way for future research and development in chronic inflammatory and autoimmune diseases.